arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Eton Pharmaceuticals, Inc.

ETON
$55.64 ▼ -1.48 (-2.59%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
36 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
32
Health
Poor
Bearish
auto_awesome

Analytical Summary

Eton Pharmaceuticals, Inc. faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.5B
Dividend Yield
Revenue Growth 98.6%
Op. Margin 34.0%
ROIC 19.3%
FCF / Share $0.26
Trailing P/E 132.5x
Price / Book 33.8x
FCF Yield 0.5%
Debt / Equity 0.41
info Valuation on last close. End-of-day price, Sep 23, 2026.

36-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$37.59M
↑ +98.6%
Net Income Profit after all expenses
$11.58M
↑ +645.0%
Operating Margin Operating profit as % of sales
34.0%
↑ +242.1% 26th
FCF / Share Free cash flow per share
$0.26
↓ -2.4%
Long-Term Debt Long-term obligations
$19.08M
↑ +0.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
38
Returns
29
Financial Health
41
Cash Quality
6

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 36 quarters